GHK-Cu across the skin
The outer skin layer is good at its job. That makes a cream a much more demanding proposition than a dish of exposed cells.
A surface with an interior
In the removed-human-skin experiment, researchers followed copper applied as GHK-Cu through different skin layers over 48 hours. They measured passage through the tissue and retention within it. Retained copper formed a local depot, a store in the skin.
I had imagined delivery as a simple crossing. The retained material complicates that picture in a useful way: the skin can be a destination as well as a barrier. Still, measuring copper leaves the fate of the intact GHK-Cu complex unresolved. This experiment examined tissue outside the body, so it supplies no direct account of a living person's cosmetic result.
The 2025 review of topical GHK puts poor passage through the stratum corneum, the outer skin layer, at the centre of the formulation problem. Its discussion of altered peptides and delivery systems explains why the cream surrounding an ingredient deserves attention alongside its name.
The copper changes the material
GHK consists of three amino acids. Binding a copper ion gives GHK-Cu; Copper Tripeptide-1 is its cosmetic ingredient name. The GHK sequence also occurs within collagen, the structural protein in skin and other tissues. The skin-regeneration review connects that chemistry with experiments on collagen production and tissue remodelling.
GHK-Cu looks self-contained on a label. I enjoy the chemistry that unsettles that impression. The complex has to remain chemically intact as well as reach the relevant tissue. Formulation research describes how strong reducing agents and low-pH ingredients can disrupt the copper complex. That is a chemical constraint, with no reliable shortcut from the ingredient name to the behaviour of a finished cream.
Collagen findings
Cell experiments and small topical studies summarised in the skin reviews report increased collagen production and improvements in some skin measures. Collagen gives tissue support; the broader remodelling work includes changes in how cells make and clear that supporting material. I trust collagen measurements more readily than the enormous word “anti-aging”.
The review of GHK and gene-expression data also describes a broad laboratory signature. Among gene changes meeting a threshold of at least 50%, 59% increased and 41% decreased. Those analyses concern GHK and cellular gene activity; the numbers do not describe the percentage of people who looked younger. GHK and copper-bound GHK-Cu require care even within this literature.
The topical review brings the argument back to delivery and small, differing human studies. A larger trial of a specified formulation, with visible skin outcomes and adequate follow-up, would be a much more satisfying next chapter than another list of affected genes.
The hair trial used a combination
The six-month trial in 45 men with androgenetic hair loss used free GHK combined with 5-aminolevulinic acid. Hair counts increased more than with placebo, and no adverse events were reported in the groups studied.
I nearly gave this paper more weight for GHK-Cu than its ingredients allow. It is a human finding about a combination containing GHK without copper. The contribution of each active ingredient remains unresolved, and the result cannot establish the effect of GHK-Cu alone. The distinction matters all the more because a hair count sounds so concrete.
Cosmetics and systemic claims
Community accounts describe firmer-feeling skin, softer lines, less shedding, irritation, dryness, breakouts and sometimes worse-looking skin nicknamed “copper uglies”. These are anecdotal accounts rather than clinical evidence. Other ingredients, expectations and uncertain product contents make their causes difficult to untangle.
The human literature discussed in the reviews is small and predominantly topical. GHK-Cu has no approved drug indication, and oral or injectable systemic use is unapproved. Human pharmacokinetic evidence for those systemic uses is lacking. Copper accumulation is a theoretical concern about systemic exposure; it has not been established as a human GHK-Cu toxicity outcome here.
I take the skin barrier as a reason to understand a topical formulation more carefully. It offers no argument for an untested route around it. The NAD+ essay follows another version of the same practical problem: knowing that a molecule matters inside cells, then trying to establish what changes there.